Clinical trial
Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease…
NCT00318149 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00318149 |
|---|---|
| Title | Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population |
| Official title | Demonstrate the Non-inferiority in Term of Cellular Mediated Immune Response of GSK Biologicals' Influenza Candidate Vaccines Containing Various Adjuvants Administered in Elderly Population (Aged 65 Years &Amp; Older) vs Fluarix™ (Known as Alpha-Rix™ in Belgium) Administered in Adults (18-40 Years) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Fluarix, Fluarix-AS25, Fluarix-AS50, Fluarix-AS01B, Fluarix-AS01E |
| Enrollment | 425 |
| Start date | Oct 10, 2005 |
| Primary completion | May 14, 2006 |
| Completion | May 14, 2006 |
| First posted | Apr 26, 2006 |
| Last update posted | Aug 8, 2018 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: